These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30706796)

  • 1. Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment.
    Onesti E; Frasca V; Ceccanti M; Tartaglia G; Gori MC; Cambieri C; Libonati L; Palma E; Inghilleri M
    CNS Neurol Disord Drug Targets; 2019; 18(3):232-238. PubMed ID: 30706796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy.
    Palma E; Reyes-Ruiz JM; Lopergolo D; Roseti C; Bertollini C; Ruffolo G; Cifelli P; Onesti E; Limatola C; Miledi R; Inghilleri M
    Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3060-5. PubMed ID: 26929355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial.
    Andresen SR; Bing J; Hansen RM; Biering-Sørensen F; Johannesen IL; Hagen EM; Rice ASC; Nielsen JF; Bach FW; Finnerup NB
    Pain; 2016 Sep; 157(9):2097-2103. PubMed ID: 27227691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients.
    Schweiger V; Martini A; Bellamoli P; Donadello K; Schievano C; Balzo GD; Sarzi-Puttini P; Parolini M; Polati E
    CNS Neurol Disord Drug Targets; 2019; 18(4):326-333. PubMed ID: 30827269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
    Impellizzeri D; Bruschetta G; Cordaro M; Crupi R; Siracusa R; Esposito E; Cuzzocrea S
    J Neuroinflammation; 2014 Aug; 11():136. PubMed ID: 25164769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of low frequency repetitive nerve stimulation in patients with myasthenia gravis and its correlation with clinical features].
    He XT; Wang LJ; Chen JL; Xie CG; Gan R; Yang R
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2443-2447. PubMed ID: 34399557
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.
    Strobbe E; Cellini M; Campos EC
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):968-73. PubMed ID: 23307959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms.
    Passavanti MB; Fiore M; Sansone P; Aurilio C; Pota V; Barbarisi M; Fierro D; Pace MC
    BMC Anesthesiol; 2017 Dec; 17(1):171. PubMed ID: 29258432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.
    Bertolino B; Crupi R; Impellizzeri D; Bruschetta G; Cordaro M; Siracusa R; Esposito E; Cuzzocrea S
    CNS Neurosci Ther; 2017 Jan; 23(1):87-98. PubMed ID: 27701827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
    Ghazizadeh-Hashemi M; Ghajar A; Shalbafan MR; Ghazizadeh-Hashemi F; Afarideh M; Malekpour F; Ghaleiha A; Ardebili ME; Akhondzadeh S
    J Affect Disord; 2018 May; 232():127-133. PubMed ID: 29486338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Effects of Ultramicronized Palmitoylethanolamide (PEA-um) in Myocardial Ischaemia and Reperfusion Injury in VIVO.
    Di Paola R; Cordaro M; Crupi R; Siracusa R; Campolo M; Bruschetta G; Fusco R; Pugliatti P; Esposito E; Cuzzocrea S
    Shock; 2016 Aug; 46(2):202-13. PubMed ID: 26844976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study.
    Ceccanti M; Libonati L; Ruffolo G; Cifelli P; Moret F; Frasca V; Palma E; Inghilleri M; Cambieri C
    Front Pharmacol; 2022; 13():982434. PubMed ID: 36052140
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson's Disease.
    Brotini S; Schievano C; Guidi L
    CNS Neurol Disord Drug Targets; 2017; 16(6):705-713. PubMed ID: 28325153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up.
    Costagliola C; Romano MR; dell'Omo R; Russo A; Mastropasqua R; Semeraro F
    J Med Food; 2014 Sep; 17(9):949-54. PubMed ID: 24827384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial.
    Ottaviani G; Rupel K; Gobbo M; Poropat A; Zoi V; Faraon M; Di Lenarda R; Biasotto M
    Clin Oral Investig; 2019 Jun; 23(6):2743-2750. PubMed ID: 30361792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of palmitoylethanolamide in a rat model of cystitis.
    Pessina F; Capasso R; Borrelli F; Aveta T; Buono L; Valacchi G; Fiorenzani P; Di Marzo V; Orlando P; Izzo AA
    J Urol; 2015 Apr; 193(4):1401-8. PubMed ID: 25463999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
    Britti D; Crupi R; Impellizzeri D; Gugliandolo E; Fusco R; Schievano C; Morittu VM; Evangelista M; Di Paola R; Cuzzocrea S
    BMC Vet Res; 2017 Aug; 13(1):229. PubMed ID: 28768536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases.
    Parisi S; Ditto MC; Borrelli R; Fusaro E
    Minerva Med; 2021 Aug; 112(4):492-499. PubMed ID: 34056884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.